Articles

Videos

Podcasts

Clinical Role

Atezolizumab (Tecentriq) is indicated for use in urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and melanoma.

Daily Medication Pearl: Atezolizumab (Tecentriq)

Aklilu Tedla, vice president of strategy and business development at Cardinal Health, discusses the cell and gene therapies in the pipeline for approval by the FDA.

Expert: Cell, Gene Therapy Research Has Weathered the Storm of COVID-19, Leaving a Bright Future Ahead

Aklilu Tedla, vice president of strategy and business development at Cardinal Health, discusses the future of pharmacies as more cell and gene therapy products become available to patients.

Expert: Cell, Gene Therapies Provide the Important Opportunity to ‘Move Beyond Chronic Disease Management to Curative Areas’

Repotrectinib awarded breakthrough therapy designation for patients with ROS1-positive metastatic non–small cell lung cancer previously treated with a ROS1 tyrosine kinase inhibitor and who were not previously administered platinum-based chemotherapy.

FDA Grants Breakthrough Therapy Designation to Repotrectinib for ROS1-Positive Metastatic NSCLC  

The SKYSCRAPER-01 trial evaluating the drug plus Tecentriq demonstrates that it did not meet its co-primary endpoint of progression-free survival.

Study Results Show Genentech’s Tiragolumab Did Not Meet Primary Endpoints

Joel Wayment, vice president of operations for 3PL Services at Cardinal Health, discusses how the pharmaceutical supply chain currently manages the transport of CAR T products to sites of administration.

Solutions to Facilitate Ease in Distribution of CAR T-Cell Therapies

Ray Tancredi, divisional vice president of Specialty Pharmacy, Development & Brand Rx/Vaccine Purchasing at Walgreens, discusses blockbuster drugs in the oncology space that have been approved this year or may be hitting the market soon.

Overview of Blockbuster Drugs in Oncology Approved in 2022, in the Pipeline for Approval in 2023

Tracy Russell, senior director, State Government Affairs at CoverMyMeds, discusses state and federal legislation that may be impacting the future of specialty pharmacies and the patient care they deliver.

State, Federal Legislation Impacting the Future of Specialty Pharmacies

First phase 3 trial in this setting shows improved overall survival rates with an immunotherapy added to chemotherapy over the standard-of-care chemotherapy alone, company says.

FDA Grants Priority Review for AstraZeneca’s Imfinzi for Those With Biliary Tract Cancer

In an interview with Pharmacy Times, Amy Pfeifer, PharmD, BCPS, CSP, of AllianceRx Walgreens Prime, discussed the important role that pharmacists can play in the treatment of prostate cancer. 

Pharmacists Play Key Roles in Treatment of Prostate Cancer

® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.